Legend Biotech stock rises to EUR 17.60, up 3.68 percent on Nasdaq

Published on 10/15/2026 at 20:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue was USD 387.50 million in second-quarter 2026. Legend Biotech stock costs EUR 17.60 on October 15, 2026, up 3.68 percent on Nasdaq.

Nasdaq move and target gap

Legend Biotech stock posted a 3.68 percent Nasdaq move on October 15, 2026.
H.C. Wainwright maintained a USD 65.00 target on October 15, 2026, 229.28 percent above the USD 19.74 Nasdaq price.
Legend Biotech stock costs EUR 17.60 at Lang & Schwarz on October 15, 2026 at 8:49 p.m. CEST, up 3.68 percent versus the Nasdaq close of October 14, 2026.
Revenue was USD 387.50 million in the second quarter of 2026.

LEGN, US52490G1022, Illustration mit AI erstellt.

Legend Biotech stock was up 3.68 percent on Nasdaq on October 15, 2026, while the euro quote reached EUR 17.60 at Lang & Schwarz. The Nasdaq move was measured against the October 14, 2026 close of USD 19.04. The euro quote stood at EUR 17.60 at Lang & Schwarz on October 15, 2026 at 8:49 p.m. CEST.

Analyst target remains above price

H.C. Wainwright reiterated its Buy rating and USD 65.00 price target on October 15, 2026, according to Investing.com. Against the USD 19.74 Nasdaq price, that target is 229.28 percent higher, using the same currency.

Revenue growth supports the picture

Legend Biotech reported USD 387.50 million of revenue in the second quarter of 2026, according to MarketBeat. The figure was 51.90 percent higher than in the year-earlier quarter, while adjusted earnings per share reached USD 0.09 against a USD 0.07 consensus estimate. The result gives the stock a fundamental counterweight to its distance from the analyst target.

Price position and valuation

On Nasdaq, Legend Biotech last traded at USD 19.74 on October 15, 2026 at 2:57 p.m. ET. The USD 16.24 to USD 37.50 52-week range puts the price 47.36 percent below the high and 21.55 percent above the low. Market capitalization stood at USD 3.7 billion, while the price-to-earnings ratio was negative 38.73.

Comparison with peers

Legend Biotech (Nasdaq, USD): plus 3.68 percent, P/E negative 38.73, market capitalization USD 3.7 billion.
Gilead Sciences (Nasdaq, USD): plus 3.33 percent, P/E negative 59.39, market capitalization USD 196.7 billion.
BioMarin Pharmaceutical (Nasdaq, USD): plus 1.00 percent, P/E 144.37, market capitalization USD 10.9 billion.

Euro quote after the Nasdaq move

Legend Biotech was trading at EUR 17.60 at Lang & Schwarz on October 15, 2026 at 8:49 p.m. CEST. The Nasdaq price was up 3.68 percent versus the USD 19.04 close of October 14, 2026. The further course of trading is shown by the continuously updated real-time quote of Legend Biotech stock.